Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.70 |
| ▸ | JAK2 | O60674 | 13/20 | 0.67 |
| ▸ | TYK2 | P29597 | 2/20 | 0.62 |
| ▸ | IKBKB | O14920 | 1/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30927824 | 0.85 | JAK1 (0.69) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL45724 | 0.85 | JAK1 (0.69) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL11916700 | 0.85 | JAK1 (0.69) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL11916701 | 0.83 | JAK1 (1.00) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL2238798 | 0.83 | JAK1 (0.66) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL13032999 | 0.82 | JAK1 (0.65) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL2185993 | 0.81 | JAK2 (0.82) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL22971286 | 0.81 | JAK1 (0.65) | JAK1JAK2TYK2IKBKBRIPK2 | |
| SCHEMBL21242583 | 0.81 | JAK1 (0.66) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL22971084 | 0.81 | JAK1 (0.63) | JAK1JAK2TYK2IKBKBRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023082839-A1 | FILGOTINIB PREPARATION METHOD | 奥锐特药业(天津)有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2017012773-A1 | SOLID FORMS OF FILGOTINIB FREE BASE | RATIOPHARM GMBH (DE) | 2017-01-26 | — | — | WO | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | JAK1 84/4885JAK2 174/4885TYK2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.